Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3613-3624

  Wang, H ^a   Nan, L ^a   Yu, D ^a   Agrawal, S ^a   Zhang, R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CAMPTOTHECIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035186743     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Human P53 cellular tumor antigen: cDNA sequence and expression in COS cells
2. The p53 pathway
3. The tumor suppressor p 53
4. p53 function and dysfunction
5. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
6. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
7. p53 mutations in human cancers
8. Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
9. Mutation of the p53 gene in human acute myelogenous leukemia
10. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
11. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
12. Mutations in the p53 gene occur in diverse human tumor types
13. Increased expression of mutant forms of p53 oncogene in primary lung cancer
14. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer
15. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas
16. P53 gene mutations in breast cancers in midwestern US women: Null as well as missense-type mutations are associated with poor prognosis
17. Expression of p53 protein in cutaneous melanoma
18. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value
19. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers
20. Participation of p53 protein in the cellular response to DNA damage
21. Thymocyte apoptosis induced by p53-dependent and independent pathways
22. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts
23. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
24. The p53-mdm2 autoregulatory feedback loop
25. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents
26. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
27. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
28. Suppression of human colorectal carcinoma cell growth by wild-type p53
29. p53 functions as a cell cycle control protein in osteosarcomas
30. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells
31. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function
32. P53 tumor suppressor gene therapy for cancer
33. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
34. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
35. MDM2 oncogene as a novel target for human cancer therapy
36. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status
37. mdm2 gene alterations and mdm2 protein expression in breast carcinomas
38. MDM2 gene amplification in human breast cancer
39. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours
40. Study of mdm2 gene amplification in primary breast tumors
41. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations
42. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma
43. P21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis
44. P53 protein expression in breast carcinoma. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1
45. An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170
46. Mdm2 expression is induced by wild type p53 activity
47. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
48. Rescue of early embryonic lethality in mdm-2-deficient mice by deletion of p53
49. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
50. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway
51. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
52. Regulation of transcription functions of the p53 tumor suppressor by the mdm2 oncogene
53. Mdm2 promotes the rapid degradation of p53
54. Regulation of p53 stability by mdm2
55. Interaction between the retinoblastoma protein and the oncoprotein MDM2
56. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
57. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes
58. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain
59. History of antisense oligonucleotides
60. Pharmacology of therapeutic oligonucleotides
61. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
62. MDM2 oncogene as a target for cancer therapy: An antisense approach
63. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression
64. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
65. Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins, natural product topoisomerase I inhibitors
66. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration
67. WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer agents 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways
68. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
69. P53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding
70. Molecular characterization of the hdm2-p53 interaction
71. Transcription factor E2F-I is upregulated in response to DNA damage in a manner analogous to that of p53
72. Mdm2: The ups and downs
73. Functions of the MDM2 oncoprotein
74. Regulation of p53 protein by MDM2 oncoprotein: Thirty eighth G. H. A. Clowes memorial award lecture
75. The MDM2 gene amplification database
76. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes
77. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
78. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms
79. Expression of MDM2 during mammary tumorigenesis
80. p53-independent role of MDM2 in TGFβI resistance
81. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53
82. A novel MDM2 anti-sense oligonulveotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer